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ttp://dx.doi.org/10.1016/j.ajpath.2014.10.007The pathogenesis of pyelonephritis caused by uropathogenic Escherichia coli (UPEC) is not well
understood. Here, we show that besides UPEC virulence, the severity of the host innate immune
response and invasion of renal epithelial cells are important pathogenic factors. Activation of
endogenous anti-inﬂammatory mediator cAMP signiﬁcantly attenuated acute pyelonephritis in mice
induced by UPEC. Administration of forskolin (a potent elevator of intracellular cAMP) reduced
kidney infection (ie, bacterial load, tissue destruction); this was associated with attenuated local
inﬂammation, as evidenced by the reduction of renal production of proinﬂammatory mediators,
renal inﬁltration of inﬂammatory cells, and renal myeloperoxidase activity. In primary cell culture
systems, forskolin not only down-regulated UPEC-stimulated production of proinﬂammatory medi-
ators by renal tubular epithelial cells and inﬂammatory cells (eg, monocyte/macrophages) but also
reduced bacterial internalization by renal tubular epithelial cells. Our ﬁndings clearly indicate that
activation of endogenous anti-inﬂammatory mediator cAMP is beneﬁcial for controlling UPEC-
mediated acute pyelonephritis in mice. The beneﬁcial effect can be explained at least in part by
limiting excessive inﬂammatory responses through acting on both renal tubular epithelial cells and
inﬂammatory cells and by inhibiting bacteria invasion of renal tubular epithelial cells. (Am J Pathol
2015, 185: 472e484; http://dx.doi.org/10.1016/j.ajpath.2014.10.007)Funded by National Natural Science Foundation of China grant NSFC
81170644 (K.L.), Henry Fok Education Foundation grant 131040 (K.L.),
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Disclosures: None declared.Urinary tract infections (UTIs) are among the most common
infectious diseases, particularly in women, babies, and the
elderly, and are the most common hospital-acquired in-
fections in the developed world, which contribute to high
ﬁnancial burden worldwide. Although antibiotics are avail-
able to treat the disease, there remain a number of challenges,
including frequent recurrence, persistence of infection, and
the increasing risk of resistance to antibiotics.1,2 For these
reasons, it is imperative to improve our understanding of the
pathogenesis of UTIs and to develop novel treatment strate-
gies that could be used to improve current treatment.
UTI usually starts as a bladder infection (cystitis) but can
develop to kidney infection (pyelonephritis) that is anstigative Pathology.
.organ- and even life-threatening condition, because it may lead
to renal scarring, chronic renal failure, sepsis, and severe sys-
temic infection with multiorgan failure.3 Uropathogenic
Escherichia coli (UPEC) is the primary cause of UTI. The
pathogenesis of UTIs can be inﬂuenced both by properties of
the infecting pathogens and host responses to pathogens, in
addition to other factors such as anatomical abnormality. Most
Cyclic AMP and Acute PyelonephritisUPEC strains express a variety of ﬁmbriae (eg, P, type 1, Dr)
that enable them to attach to uroepithelial cells (a critical step in
colonization). On contact with uroepithelial cells, UPEC lib-
erates toxins (eg, hemolysin and cytotoxic necrotizing factor-1)
which mediate direct injury to the cells, disrupting the mucosal
barrier, and opening access to the underlying tissue.4 UPEC is
also able to transiently invade, survive, and multiply within
uroepithelial cells, which is thought to enable organisms to
evade host defenses and to act as a reservoir for further infec-
tion. In addition, most human UPEC strains are resistant to
complement-mediated killing5,6 but exploit complement for
entering epithelial cells that contribute to kidney infection.7,8
UPEC has evolved mechanisms through carrying intracellular
Toll/IL-1 receptor domain homologous sequences to impair
immune protection while promoting inﬂammation and tissue
damage.9
Besides the properties of UPEC, the host immune
response to pathogens has a big effect on the pathogenesis
of UTI. Although innate immune responses play essential
roles in the ﬁrst line of host defense against pathogens, they
also cause harm when present in excess or are dysregulated.
For example, in the acute condition, uroepithelial cells and
inﬂammatory cells, in response to UPEC stimulation, pro-
duce a number of proinﬂammatory mediators [eg, IL-6,
tumor necrosis factor (TNF)-a, and IL-8], which (if present
in excess) cause epithelial inﬂammation/damage, allowing
bacteria to enter the underlying tissue.10 In addition, if the
activation of neutrophils is not tightly regulated, the reactive
oxygen species (ROS) and cytotoxic enzymes and ingested
bacteria could be released into the surrounding area, causing
tissue destruction and pathogen survival/dissemination.11
Previous studies in acute pyelonephritis have found that
paradoxically Tlr4/, Il-1b/, or C3/ mice had less
severe acute kidney infection and inﬂammation, suggesting
that innate immune responses driven by TLR-4 signaling,
proinﬂammatory cytokine IL-1b, or complement effector
molecules are harmful, instead of beneﬁcial for the host.7,12
More than half a century after its discovery cAMP remains
the object of intense scientiﬁc interest.13 cAMP is an intra-
cellular second messenger induced by extracellular signals
such as hormones, inﬂammatory mediators, and cytokines. It
induces intracellular signal transduction conveying the cAMP-
dependent pathways to regulate diverse cellular responses.14
Among the diverse functions, cAMP is known as a potent
anti-inﬂammatory mediator, having inhibitory effects on
production of proinﬂammatory cytokines in immune cells,15
leukocyte chemotaxisis,16 and release of bioactive molecules
and cytotoxic agents from granulocytes.17 In addition, cAMP
is found to regulate exocytic process in a variety of cells18 and
to induce exocytosis of E. coli from bladder epithelial cells,
thus reducing E. coli colonization of bladders.19
Forskolin, a potent activator of cAMP, is used for inves-
tigating the role of cAMP in various cellular processes and
diseases. Previous human and animal studies have found that
administration of forskolin is beneﬁcial in several clinical
disorders, including UTI, bronchoconstriction, ischemiaThe American Journal of Pathology - ajp.amjpathol.orgreperfusion injury, high blood pressure, and leukemia.19e23
Although forskolin was studied in experimental UTI and
showed that forskolin treatment reduces bladder infection
(cystitis),19 it is unknown whether forskolin treatment would
be effective in kidney infection (pyelonephritis). Here, we
evaluated the effect of forskolin on protection against murine
acute pyelonephritis and explored cellular and molecular
mechanisms by which forskolin confers the protection. Our
results indicate that forskolin treatment signiﬁcantly reduced
kidney infection and suggest that forskolin mediated the
suppression of excessive inﬂammatory responses and inhi-
bition of E. coli invasion of renal tubular epithelial cells
(RTECs) that are responsible for the protection.
Materials and Methods
Materials
Forskolin, hydroxyurea, hydrocortisone, tri-iodothyronine,
and thioglycollate were from Sigma-Aldrich (Shanghai,
China). Collagenase D was from Roche (Welwyn, UK). The
antibodies for CD45 (30-F11, allophycocyanin), Gr-1 (RB6-
8C5, phosphatidylethanolamine), F4/80 (BM8, phosphati-
dylethanolamine), Ly6G (1A8, phosphatidylethanolamine),
and CD11b (M1/70, ﬂuorescein isothiocyanate) were from
BioLegend (San Diego, CA). Horseradish peroxidase-
conjugated rabbit anti-rat polyclonal antibody was from
Dako (Cambridge, UK). FcR blocking antibody (CD16/32,
2.4G2) and mouse ELISA kits for TNF-a, IL-6 were from
BD Biosciences (San Jose, CA). Myeloperoxidase (MPO)
assay kit and mouse ELISA kit for keratinocyte chemo-
attractant (KC) and Parameter cAMP assay kit were from
R&D Systems (Shanghai, China). Cell culture medium, fetal
calf serum, insulin-transferring-selenium solution, genta-
micin, and CountBright absolute counting beads were pur-
chased from Invitrogen China Limited (Beijing, China).
Induction of Pyelonephritis and Forskolin
Administration
Murine UTI, a model of ascending urinary tract infection
leading to pyelonephritis, was induced in female C57BL/6
mice (8 to 10 weeks old) by bladder inoculation of human
UPEC strain J96 [108 colony-forming unit (CFU) in 50 mL
of phosphate-buffered saline (PBS); serotype O4; K6, it is
a serum-resistant, hemolysin-secreting E. coli strain that
expresses both type 1 and P ﬁmbriae)] per urethra as previ-
ously described.7,24 Forskolin (10 mg/kg) or vehicle control
(25% of dimethyl sulfoxide in PBS) was given daily by i.p.
injection, starting at 1 hour before or 1 hour after the inoc-
ulation. The effect of the forskolin treatment was conﬁrmed
by measuring tissue cAMP amounts in the kidneys 2 hours
after the administration. Results indicate that kidney cAMP
amounts were clearly increased in forskolin-treated mice
compared with that in control-treated mice [forskolin versus
control (mean  SEM): 1176  50 versus 926  139 pmoL/473
Wei et almg wet wt; n Z 3; P < 0.05]. In some experiments, before
the forskolin administration and induction of UTI, mice were
treated by i.p. injection of 20 mg of hydroxyurea per mouse
daily for 7 days and 100 mg of anti-mouse Gr-1 antibody per
mouse on the last day of treatment to deplete neutrophils as
previously described.25 C57BL/6 mice were purchased from
Vital River Laboratories (Beijing, China). The Ethics Review
Committee for Animal Experimentation at Xi’an Jiaotong
University approved and oversaw all mouse experiments.
Assessment of Bacterial Load in the Kidney
Total bacterial load in kidney tissues was analyzed by the
agar plate assay as previously described with modiﬁcations.26
In brief, the kidney was weighed and subsequently homog-
enized in 2 mL of PBS. One hundred microliters of a series
dilution of homogenates was plated on cysteine lactose
electrolyte deﬁcient (CLED) plates. After incubation for 24
hours, bacterial CFU on agar plates were manually counted
and expressed as CFU per gram of kidney tissue.
Assessment of Renal Pathology
To assess renal pathology, the kidney was ﬁxed in a solution
of 4% formalin in PBS for 24 hours and embedded in parafﬁn.
Sections (3 mm) were stained with hematoxylin and eosin. The
severity of renal pathology (ie, cellular inﬁltration, tissue
destruction, bacterial patchiness, abscess) was graded in a
blinded fashion by two investigators (N.W. and B.-S.G.) with
the use of a 7-point scale as described previously with mod-
iﬁcations,27 in which 0, 1, 2, and 3 indicated normal, mild,
moderate, and severe pyelitis, respectively (pathologic changes
were mainly located at papilla and medulla); whereas 4, 5, and
6 indicated mild, moderate, and severe pyelonephritis,
respectively (pathologic changes were distributed to papilla,
medulla, and cortex).
Assessment of Inﬂammatory Cell Inﬁltration in the
Kidney
Single renal cell suspension was prepared with the method
described previously with modiﬁcations.28 Kidneys were
weighed, minced, and incubated with 0.75 mg/mL collagenase
D for 10 minutes at 37C with gentle agitation. The colla-
genase was inactivated with an equal volume of Dulbecco’s
modiﬁed Eagle’s medium (DMEM)-F12 that contained 10%
fetal calf serum. The digested tissue mixture was then
passed through a 40-mm nylon sieve to remove tissue debris.
The cell segments were collected and treated with red cell
lysis buffer to remove remaining red blood cells. The cell
pellet was washed and re-suspended in PBS that contained
1% bovine serum albumin and was followed by ﬂow cyto-
metric analysis. The cells were pre-incubated with FcR
blocking antibody (CD16/32) and then stained with
ﬂuorochrome-conjugated monoclonal antibodies or the
appropriate isotype control antibodies at 4C for 20 minutes.474To quantify absolute cell counts in kidney tissue, we used
CountBright absolute counting beads in our ﬂow cytometric
assays according to the instructions of the manufacturer.
All ﬂow cytometric analysis was performed with Calibur
Flow Cytometer (BD Biosciences) and FlowJo software
version 7.6.5 (TreeStar Inc., Ashland, OR).
Immunohistochemical Staining
Frozen sections (4 mm) of OCT-embedded kidneys were air-
dried for a minimum of 20 minutes at room temperature and
then acetone ﬁxed. Sections were incubated with rat anti-
mouse Gr-1 or F4/80 antibody and followed by horseradish
peroxidase-conjugated rabbit anti-rat antibody.
Cell Cultures and Treatment
Primary tubular epithelial cell cultures were prepared from
kidneys of naive male C57BL/6 mice as described previ-
ously.29 In brief, minced cortex was digested with 0.1%
collagenase II and passed through a 40-mm nylon sieve.
The cells and tubules were collected and cultured in a
DMEM-12 medium that contained 2% fetal calf serum,
5 mg/mL insulin, 5 mg/mL transferrin, 5 ng/mL selenium, 40
ng/mL hydrocortisone, and 1012 mol/L tri-iodothyronine.
Nonpassaged 7-day cultured cells were used. Neutrophils
and macrophages were prepared from peritoneal lavage of
C57BL/6 mice after i.p. injection of 1 mL of 3% thio-
glycollate. For neutrophils, peritoneal cells were harvested
at 24 hours after thioglycollate injection and cultured for 1
hour to discard adherent cells and to collect suspension cells
for further analysis. For macrophages, peritoneal cells were
harvested at 5 days after thioglycollate injection and
cultured for 1 hour to discard suspension cells and to collect
adherent cells for further analysis.
To assess the effect of forskolin on mRNA expression of
proinﬂammatory mediators in these cells, conﬂuent layers of
RTECs grown on 24-well plates or 2 106/well neutrophils or
macrophages (prepared as described in the previous para-
graph) seeded in 24-well plates were incubated with or without
10 mmol/L forskolin, in the presence of 2  106/well of heat-
killed J96, for 4 hours at 37C, in 1 mL of total volume.
Semiquantitative Real-Time RT-PCR
Total RNA extraction from kidney and cell samples, reverse
transcription reaction, and the PCR were performed as
previous described.30 The relative gene expression was
analyzed with the 2DDCT method31 and expressed as
2DD(Ct), where Ct is cycle threshold,
DDðCtÞZ testing samplesDðCtÞ  control samplesDðCtÞ; ð1Þ
D ðCtÞZ testing gene ðCtÞ  18s ðCtÞ: ð2Þ
The control samples were either normal kidney tissues or
untreated cells. The testing samples were infected kidneyajp.amjpathol.org - The American Journal of Pathology
Table 1 PCR Primer Sequences and Product Sizes
Primer* Oligonucleotide sequence Product size (bp) GeneBank code
18S-1 50-ATCCCTGAGAAGTTCCAGCA-30 153 NM_011296.1
18S-2 50-CCTCTTGGTGAGGTCGATGT-30
TNF-a-1 50-TGAGCACAGAAAGCATGATCC-30 200 NM_013693.3
TNF-a-2 50-GCCATTTGGGAACTTCTCATC-30
IL1b-1 50-GCCCATCCTCTGTGACTCAT-30 230 NM_008361
IL1b-2 50-AGGCCACAGGTATTTTGTCG-30
KC-1 50-TGAAGCTCCCTTGGTTCAGA-30 361 NM_008176.3
KC-2 50-TGCACTTCTTTTCGCACAAC-30
IFNg-1 50-ACTGGCAAAAGGATGGTGAC-30 237 NM_008337.3
IFNg-2 50-TGAGCTCATTGAATGCTTGG-30
IL6-1 50-GTTCTCTGGGAAATCGTGGA-30 339 NM_031168
IL6-2 50-GAAATTGGGGTAGGAAGGA-30
MCP-1-1 50-GGCTCAGCCAGATGCAGTTA-30 219 NM_011333.3
MCP-1-2 50-ATTTGGTTCCGATCCAGGTT-30
MIP-1a-1 50-CACTGCCCTTGCTGTTCTTC-30 262 NM_011337.2
MIP-1a-2 50-GGCATTCAGTTCCAGGTCAG-30
MIP-2a-1 50-CCCAGCTCTGTGCAAACCTA-30 248 NM_009140
MIP-2a-2 50-TCTGCCTCTTTTGGTCAGGA-30
RANTES-1 50-GTGCCCACGTCAAGGAGTAT-30 186 NM_013653
RANTES-2 50-GGGAAGCGTATACAGGGTCA-30
*Primer-1 is identical to the coding strand; primer-2 is complementary to the coding strand.
KC, keratinocyte chemoattractant; IFN, interferon; MCP, monocyte chemoattractant protein; MIP, macrophage inﬂammatory protein; RANTES, regulated on
activation normal T cell expressed and secreted; TNF, tumor necrosis factor.
Figure 1 Forskolin administration reduces bacterial load in the kidneys.
Bacterial loads in kidneys were examined at 6, 24, and 48 hours after
inoculation of J96. For the 6-and 24-hour groups, a single administration
of forskolin or vehicle control was given at 1 hour after the inoculation. For
the 48-hour group, an additional administration of forskolin was given at
24 hours after the inoculation. Each dot represents a single animal and is
shown as the average number of two replicate agar plates; horizontal lines
represent the means of CFU counts. *P < 0.05, **P < 0.01, Mann-Whitney
test. CFU, colony-forming unit; Fsk, forskolin.
Cyclic AMP and Acute Pyelonephritistissues or forskolin-treated cells. The information for primer
sequences is given in Table 1.
ELISA and MPO Assays
TNF-a, IL-6, and KC amounts in urine and kidney ho-
mogenate were measured by a 96-well plate method with
murine IL-6 and KC ELISA kits. Renal MPO activity was
measured in kidney homogenate by a speciﬁc ELISA
method with MPO assay kit according to the instructions
of the manufacturer. Mouse kidney was weighed and
homogenated in PBS that contained 1% Triton X-100, 1
mmol/L EDTA, and 1% protease inhibitor cocktail (Sigma-
Aldrich) and spin cleared at 10,000  g for 10 minutes as
previously described.32 The resulting supernatants were
subjected to ELISA and MPO assays. Urine samples were
collected at the end of the experiment when mice were
sacriﬁced.
Bacterial Binding and Internalization Assays
The assays were performed as we have described previ-
ously.8 Brieﬂy, mouse RTECs were primarily cultured on 24-
well plates and grown to conﬂuence. RTECmonolayers were
preincubated with or without forskolin for 2 hours; bacteria
(J96, 1  107 CFU/well) were then added and incubated for
an additional 1 hour at 37C. For binding assay, cells were
vigorously washed to remove unattached bacteria and lyzed
with sterile H2O, and the lysate was plated onto CLED plates.
The colonies were counted, and results were expressed as
CFU per well. For internalization, after washing, the cellsThe American Journal of Pathology - ajp.amjpathol.orgwere incubated for 1 hour with 100 mg/mL gentamicin to kill
extracellular bacteria and lyzed. The lysate was plated onto
CLED plates, and the colonies were counted.
Bacterial Exocytosis Assay
Bacterial exocytosis assay was performed as described
previously.19 Brieﬂy, RTEC monolayers were incubated
with bacteria for 1 hour at 37C. After washing, the cells
were incubated for 1 hour with 100 mg/mL gentamicin to
kill extracellular bacteria. After additional washes, the cells
were incubated with medium with or without forskolin for475
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Figure 2 Forskolin administration attenuates renal pathology after the infection. A: Representative images of hematoxylin and eosinestained kidneys
from the control and forskolin-treated mice show renal histological changes including cellular inﬁltration, bacterial patchiness, abscess, and tubule
destruction (arrows). B: Histologic scores in the control (black dots) and forskolin-treated (white dots) mice. Each dot represents a single animal; horizontal
lines represent the means of renal pathological scores. *P < 0.05, **P < 0.01, Mann-Whitney test. Original magniﬁcation, 100. Fsk, forskolin.
Wei et alan additional 2 hours at 37C. The supernatant was plated
onto CLED plates. The percentage of bacterial exocytosis
was calculated as the number of bacteria in the superna-
tants divided by the total number of bacteria surviving
incubation with gentamicin (including intracellular and
exited bacteria). In some experiments, 5 mmol/L H89 was
added to the medium as an inhibitor of cAMP signal
pathway.476Statistical Analysis
Data are expressed as means  SEM or the readout of
individual mice. Mann-Whitney test, Student’s t-test, or
analysis of variance was used when appropriate to deter-
mine signiﬁcant differences between samples. All of the
analyses were performed with GraphPad Prism software
version 5 (GraphPad Inc., San Diego, CA).ajp.amjpathol.org - The American Journal of Pathology
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Figure 3 Forskolin administration reduces
renal production of proinﬂammatory mediators
after the infection. A: Semiquantitative analysis of
proinﬂammatory mediator mRNA expression in the
kidney tissue from the control and forskolin-
treated mice at 6 hours after infection. The rela-
tive changes in gene expression were analyzed
with the 2DDCT method. The dashed lines
indicate basal levels of mRNA expression in normal
tissue. B: ELISA shows TNF-a, IL-6, and KC protein
expression in the kidney tissue from the control
(black dots) and forskolin-treated (white dots)
mice at different time points after infection. C:
ELISA shows urine concentrations of TNF-a, Il-6,
and KC in the control and forskolin-treated mice
at 6 and 24 hours after infection. Each dot rep-
resents a single animal and is shown as the mean
of two replicate PCR results; horizontal lines
represent the means of arbitrary units of mRNA
expression (A). Data are expressed as
means  SEM (B and C). n Z 6 mice per group
(A); nZ 4 to 8 mice per group at each time point
(B and C). *P < 0.05, **P < 0.01, Student’s t-
test. Ctrl, control; Fsk, forskolin; KC, keratinocyte
chemoattractant; MCP, monocyte chemoattractant
protein; MIP, macrophage inﬂammatory protein;
RANTES, regulated on activation normal T cell
expressed and secreted; TNF-a, tumor necrosis
factor-a.
Cyclic AMP and Acute PyelonephritisResults
Forskolin Reduces Bacterial Load in Kidneys and
Attenuates Renal Pathology
Previous studies in murine acute nephritis have found that
renal infection (detecting viable bacteria in kidneys and renal
tissue damage) appears as early as 4 hours after bladder
inoculation of UPEC and peaks within 48 to 72 hours.26 We
therefore assessed the effects of forskolin on renal infection at
three time points (6, 24, and 48 hours after infection). We
initially pretested two protocols of forskolin administration,
which involved the start of administration at 1 hour before or 1
hour after the onset of infection, aiming to assess the possible
roles for forskolin in prevention and treatment of infection,
respectively. We found that both protocols of forskolin
administration provided similar protection against kidney
infection at 6 and 24 hours after infection. Because the pro-
tocol for administering forskolin after the onset of infection is
more relevant to clinical practice, it was used in the rest of theThe American Journal of Pathology - ajp.amjpathol.orgexperiments. Bacterial loads in the kidneys were signiﬁcantly
reduced in the forskolin-treated group by 10- to 100-fold
compared with the control group at all time points (6, 24,
and 48 hours) (Figure 1). In addition to bacterial loads, we also
assessed the effect of forskolin treatment on renal histopa-
thology. Renal histopathologic changes, including cellular
inﬁltration, tissue inﬂammation, and mild tissue destruction,
were detected at 6 hours after infection, which was mainly
located at papilla and medulla. At 24 hours after infection,
renal histopathologic changes became manifest. Cellular
inﬁltration, bacterial patchiness, abscess, and tubule destruc-
tion were observed at papilla/medulla and cortex. At 48 hours
after infection, cellular inﬁltration and bacterial patchiness
were reduced or cleared, which left some cavities at papilla/
medulla and cortex. On the basis of these histopathologic
changes, we performed histologic scoring in individual mice
of the two groups. Our results showed that, compared with the
control group, the forskolin-treated group exhibited attenuated
renal histopathology at all time points (6, 24, and 48 hours)
(Figure 2). We also assessed renal function in the two groups477
Wei et al
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Cyclic AMP and Acute Pyelonephritisofmice (control and forskolin treated) at all studied time points
(6, 24, and 48 hours) after infection by measuring blood urea
nitrogen concentrations. Results show that blood urea nitrogen
concentrations were only slightly elevated in some infected
mice compared with naive mice but did not differ signiﬁcantly
between the control and forskolin-treated groups
(Supplemental Figure S1). These results suggest that renal
functional impairment may not be an important index for renal
pathology in this model; in consequence the beneﬁcial effect
of forskolin cannot be identiﬁed in this context.
Forskolin Reduces Renal Production of
Proinﬂammatory Mediators after the Infection
Kidney infection induced by UPEC triggers the production of
proinﬂammatory mediators by epithelial cells and inﬂam-
matory cells rapidly. We therefore evaluated the effects of
forskolin on renal production of proinﬂammatory cytokines
and chemokines in response to bacterial stimulation. Intra-
renal mRNA expression of inﬂammatory cytokines [ie, IL-6,
IL-1b, interferon (IFN)-g, TNF-a] and chemokines [ie, KC,
regulated on activation normal T cell expressed and secreted
(RANTES), monocyte chemoattractant protein (MCP)-1,
macrophage inﬂammatory protein (MIP-)1a, MIP-2a] was
signiﬁcantly reduced in the forskolin-treated group compared
with the control group at 6 hours after infection (Figure 3A).
Intrarenal protein expression of TNF-a, IL-6, and KC was
also reduced in the forskolin-treated group compared with the
control group after the infection, particularly at 6 and 24
hours (Figure 3B). In addition to renal tissue, we also
analyzed the concentrations of these proteins in the urine.
TNF-a, IL-6, and KC were not detectable in normal mouse
urine but were clearly detected in the infected mouse urine at
6 and 24 hours after infection. Compared with the control
group, the forskolin-treated group had lower concentrations
of TNF-a, IL-6, and KC (Figure 3C). Together, these results
indicate that forskolin treatment down-regulated renal pro-
duction of an array of proinﬂammatory mediators in response
to bacteria stimulation.
Forskolin Reduces Renal Inﬂammatory Cell Inﬁltration
after the Infection
In addition to renal tissue destruction, renal inﬂammatory
cell inﬁltration, particularly neutrophils, is a characteristicFigure 4 Forskolin administration reduces renal leukocyte inﬁltration after the
and F4/80 in the kidneys from control and forskolin-treated mice at 24 hours afte
treated mice at different time points after infection. C: Flow cytometric analysis o
at different time points after infection by gating CD45þ, CD45þGr-1þ, and CD45þF
basal amount of renal inﬂammatory cells. Representative ﬂow cytometric dot plot o
control-treated mice. Quantiﬁed numbers of CD45þ, Gr-1þ, and F4/80þ cells in the k
cellular inﬁltration in the kidneys from control and forskolin-treated mice at 24 ho
diagram of gating strategy, quantiﬁed numbers of CD45þLy6Gþ and CD45þLy6GC
expressed as means  SEM (B); horizontal lines represent the means of cell numb
represents a single animal (C and D). *P < 0.05 compared with the control treatm
Original magniﬁcation, 100. Ctrl, control; Fsk, forskolin; MPO, myeloperoxidase;
The American Journal of Pathology - ajp.amjpathol.orgpathologic change in acute pyelonephritis. To assess the ef-
fect of forskolin on cellular inﬁltration, we performed
immunohistochemistry for Gr-1 and F4/80 on kidney tissues
at 24 hours after infection. Although Gr-1þ and F4/80þ cells
were found in the kidneys of both the control and forskolin-
treated mice, the number of these cells, particularly Gr-1þ
cells, was less prominent in the kidneys of the forskolin-
treated mice than that of the control mice (Figure 4A). We
also performed renal tissue MPO assay in both the control
and forskolin-treated mice, at various time points (0, 6, 24,
and 48 hours) after the infection. MPO activity was signiﬁ-
cantly lower in the forskolin-treated group than in the control
group (Figure 4B), which was consistent with the immuno-
histochemistry data. To quantify cellular inﬁltration in the
kidney tissues, we performed ﬂow cytometric analysis for
CD45, Gr-1, and F4/80 in single-cell suspension prepared
from individual kidneys of the control and forskolin-treated
mice. At 6 hours after infection, forskolin had no apparent
effects on the numbers of inﬁltrating cells. However, at 24
and 48 hours after infection, the numbers of CD45þ,
CD45þGr-1þ, and CD45þF4/80þwere signiﬁcantly reduced
in the forskolin-treated group compared with the control
group (Figure 4C). Because Gr-1þ and F4/80þ may not be
absolutely speciﬁc for neutrophils and monocytes/macro-
phages, respectively, we performed more speciﬁc analysis of
renal cellular inﬁltration by using several additional anti-
bodies and relevant gating strategies to assess the inﬂuence of
forskolin on renal neutrophil and monocytes/macrophage
inﬁltration. Results show that the number of CD45þLy6Gþ
cells (highly speciﬁc for neutrophils) and CD45þLy6G-
CD11bþ cells (highly speciﬁc for monocytes/macrophages)
was signiﬁcantly reduced in the kidneys of the forskolin-
treated mice than that of the control mice at 24 hours after
infection (Figure 4D). These results are in agreement with the
observations that the number of Gr1þ and F4/80þ cells was
reduced in the kidneys of the forskolin-treated mice
(Figure 4C), indicating that forskolin treatment reduced renal
neutrophil and macrophage inﬁltration after infection.
Forskolin Down-Regulates Proinﬂammatory Mediator
Production by RTECs and Inﬂammatory Cells
Our data presented so far indicate that forskolin adminis-
tration protected mice from acute pyelonephritis, as evi-
denced by the reduction of bacterial load, tissue damage,infection. A: Representative images of immunohistochemical staining for Gr1
r infection. B: MPO activity in the kidney tissue from control and forskolin-
f cellular inﬁltration in the kidneys from control and forskolin-treated mice
4/80þ cells. The kidney tissue from uninfected mice was used to indicate a
f CD45, Gr-1, and F4/80 expression in renal cell suspension prepared from the
idneys from control and forskolin-treated mice. D: Flow cytometric analysis of
urs after infection by gating CD45þLy6Gþ and CD45þLy6GCD11bþ cells. A
D11bþ cells in the kidneys from control and forskolin-treated mice. Data are
ers (C and D). nZ 5 to 7 mice per group at each time point (B); each dot
ent, Student’s t-test (B); *P < 0.05, **P < 0.01, ***P < 0.001 (C and D).
Normal, uninfected; SSC, side scatter.
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Wei et aland inﬂammatory responses within the kidneys. To explore
cellular mechanism by which forskolin restricts production
of proinﬂammatory mediators within kidneys, we used
primary cell culture systems for RTECs and inﬂammatory
cells to assess the effects of forskolin on proinﬂammatory
mediator production by these cells in response to bacteria
stimulation. Incubation with heat-killed E. coli markedly up-RTEC
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480regulated mRNA expression of all examined cytokines (ie,
IL-1b, TNF-a, IFN-g, and IL-6) and chemokines (ie, KC,
MCP-1, RANTES, MIP-1a, and MIP-2a) by RTECs and
macrophages and neutrophils. In the presence of forskolin,
mRNA expression amounts for several key proinﬂammatory
mediators were signiﬁcantly reduced in RTECs (ie, KC,
IL-1b, TNF-a, MCP-1, MIP-1a, and RANTES) and mac-
rophages (ie, KC, IL-1b, TFN-a, MCP-1, MIP-1a, and
IFN-g) compared with that in the absence of forskolin. In
addition, forskolin treatment also reduced IL-1b and TNF-a
mRNA expression in neutrophils (Figure 5). Thus, our data
indicate that forskolin has an inhibitory effect on the pro-
duction of proinﬂammatory mediators by RTECs and in-
ﬂammatory cells in response to E. coli; the effects were
more prominent in RTECs and macrophages, in terms of the
range of proinﬂammatory mediators that is affected.
Critical Role for Forskolin in Limiting E. coli Invasion of
RTECs
In addition to the mechanism of restricting inﬂammatory
responses within the kidney, we also hypothesized that
forskolin may play important roles in limiting E. coli in-
vasion of RTECs which would confer the protective effects.
To investigate this, using primary cultured RTECs, we
assessed the effects of forskolin on bacterial binding to and
internalization by RTECs. RTECs were preincubated with
forskolin and then cocultured with bacteria (J96) and fol-
lowed by binding and internalization assays. Forskolin
treatment had no apparent effects on bacteria binding, but it
signiﬁcantly reduced the number of viable intracellular
bacteria and enhanced the number of viable bacteria that had
exited the cells (exocytosis) (Figure 6, AeC). Because the
above experiments were performed under a condition that
forskolin was present in the coculture of bacteria and
RTECs, although the RTECs were pretreated with forskolin,
the effects of forskolin may not be entirely attributed to the
action on RTECs. To assess the possibility of forskolin
having direct effects on bacteria to inhibit their ability to
invade epithelial cells, bacteria (J96) were preincubated with
forskolin, and the washed bacteria were then used for
analyzing their growth and ability to invade RTECs. Results
show that forskolin pretreatment did not affect such pros-
perities of bacteria (Supplemental Figure S2). We alsoFigure 5 Forskolin down-regulates proinﬂammatory mediator produc-
tion by RTECs and inﬂammatory cells in response to bacteria stimulation.
Semiquantitative analysis of proinﬂammatory mediator mRNA expression in
the control and forskolin-treated primary cultured RTECs (A) and freshly
prepared peritoneal macrophages (B) and neutrophils (C). The relative
changes in gene expression were analyzed with the 2DDCT method. The
dashed line indicates a basal amount of mRNA expression in the cells not
being exposed to J96 and forskolin. Data are expressed as means  SEM.
nZ 4. *P < 0.05, **P < 0.01, Student’s t-test. Ctrl, control; Fsk, forskolin;
KC, keratinocyte chemoattractant; MCP, monocyte chemoattractant protein;
MIP, macrophage inﬂammatory protein; RANTES, regulated on activation
normal T cell expressed and secreted; RTEC, renal tubular epithelial cell;
Tnf-a, tumor necrosis factor-a.
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Figure 6 Critical role for forskolin in limiting UPEC invasion of
RTECs. A: Effect of forskolin on bacterial binding to RTECs. B: Effect of
forskolin on intracellular population of E. coli in RTECs. C: Effect of
forskolin on bacterial exocytosis by RTECs. D: Effect of forskolin on
intracellular cAMP in RTECs. E: Effect of H89 on intracellular population
of E. coli in RTECs. F: Effect of H89 on bacterial exocytosis by RTECs.
Data are expressed as means  SEM. n Z 4 (AeD). *P < 0.05,
**P < 0.01, ***P < 0.001, Student’s t-test. CFU, colony-forming unit;
Fsk, forskolin; RTEC, renal tubular epithelial cell; UPEC, uropathogenic
Escherichia coli.
Cyclic AMP and Acute Pyelonephritisassessed the possibility of forskolin having an effect on
viability of the host cells, which may inﬂuence the cell
functions. RTECs were preincubated with forskolin, and the
washed cells were then used for analyzing their viability and
uptake capacity. Results show that the viability of forskolin-
treated RTECs was comparable with that of control-treated
RTECs, whereas the uptake of bacteria was signiﬁcantly
reduced in forskolin-treated RTECs compared with control-
treated RTECs (Supplemental Figure S3). Collectively,
these data suggest that forskolin-mediated reduction of
E. coli invasion of RTECs is mainly through their speciﬁc
actions on RTECs rather than acting on bacteria or causing
RTEC death.
To further investigate whether the effects of forskolin on
bacteria internalization by RTECs are through activating
cAMP, we measured intracellular cAMP amounts of RTECs
after forskolin stimulation and assessed whether intracellular
bacteria and exocytosis of bacteria by RTECs depend on
cAMP signals. As we expected, the cAMP amounts were
increased by forskolin treatment in a dose-dependent
manner (Figure 6D) and inhibition of cAMP signal
pathway by H89 [a potent protein kinase A (PKA; cAMP-
dependent) inhibitor] abolished the effects of forskolin on
intracellular population of E. coli and exocytosis (Figure 6,
E and F).The American Journal of Pathology - ajp.amjpathol.orgForskolin Mediates Protective Effect on Kidney
Infection through Acting on Renal Parenchymal Cells
Data from cell culture experiments suggested important
roles for forskolin in limiting E. coli invasion of RTECs and
in down-regulating production of proinﬂammatory media-
tors by RTECs. To assess the possibility that forskolin
mediates its protective effect on kidney infection through
acting on renal parenchymal cells, we evaluated the effects
of forskolin on kidney infection in neutrophil-depleted mice.
After neutrophil depletion, peripheral blood neutrophil
count was signiﬁcantly reduced (by 85% to 90% reduction),
and no neutrophils were detected in kidney tissues
(Figure 7A). Depletion of neutrophils not only reduced
bacterial load in the kidneys (Figure 7B) but also attenuated
tissue destruction (Figure 7, C and D). Administration of
forskolin in neutrophil-depleted mice further reduced bac-
terial load in the kidneys and tissue destruction, compared
with the control treatment (Figure 7, BeD).Discussion
Innate immunity is the ﬁrst line of immunity against
infection; however, excessive innate immune responses are481
Figure 7 Forskolin mediates protective effect on kidney infection
through acting on renal parenchymal cells. A: Representative ﬂow cytom-
etry dot plot of Gr-1þ cells in peripheral blood and renal cell suspension
from neutrophil-depleted and nondepleted mice. B: Bacterial loads in the
kidneys of noneneutrophil-depleted mice and neutrophil-depleted mice
that received forskolin or control treatment at 24 hours after infection.
C: Representative images of kidneys of the mice mentioned in B stained with
hematoxylin and eosin (papilla/medullar) or periodic acid-Schiff (cortex),
showing lesions (arrows). D: Histologic scores of the kidneys mentioned in
B. Each dot represents a single animal and is shown as the average number of
two replicate agar plates; horizontal lines indicate the means of CFU counts.
*P < 0.05, **P < 0.01, Mann-Whitney test. Scale bar Z 100 mm (D).
Original magniﬁcation, 200. Fsk, forskolin; N depl, neutrophil-depleted;
non-depl, noneneutrophil-depleted.
Figure 8 A proposed mechanism by which forskolin confers the pro-
tection against murine acute pyelonephritis. Administration of forskolin
leads to elevation of intracellular cAMP, which mediates the inhibition of
inﬂammatory cell migration, down-regulation of the production of proin-
ﬂammatory mediators by RTECs and inﬂammatory cells, and limitation of
bacteria invasion of RTECs. All of these effects contribute to the attenua-
tion of cellular inﬁltration, bacteria load, and tissue damage in the kidneys
of forskolin-treated mice. Mo, monocyte; Mf, macrophage; RTEC, renal
tubular epithelial cell.
Wei et alimplicated in the pathogenesis of a number of clinical dis-
orders, including inﬂammatory and infectious dis-
eases.12,30,33,34 Thus, therapies to prevent severe acute and
chronic inﬂammatory states may have beneﬁcial effects in
such clinical disorders. In UTI, previous studies found that
treatment of UPEC-infected mice with forskolin protected
mice from bladder infection.19 The present study not only
extends the previous ﬁndings by showing that forskolin482administration protected mice from acute pyelonephritis
(a more severe type of UTI) but also reveals potential
cellular and molecular pathways by which forskolin confers
the protection.
To understand how forskolin confers the protection
against murine acute pyelonephritis, we performed a series
of in vivo/ex vivo and in vitro cell culture experiments to
dissect the effects of forskolin on inﬂammatory cells and
RTECs. For inﬂammatory cells, consistent with the known
anti-inﬂammatory property of forskolin/cAMP in leuko-
cytes, our in vivo/ex vivo data indicate that forskolin treat-
ment signiﬁcantly reduced the number of leukocytes,
particularly neutrophils within the kidneys after the infec-
tion, and our in vitro cell culture data indicate that forskolin
had inhibitory effects on the production of proinﬂammatory
mediators by inﬂammatory cells, particularly macrophages
in response to bacteria stimulation. Furthermore, the data
from the neutrophil depletion experiment indicate that
depletion of neutrophils not only attenuated tissue destruc-
tion but also to a less extent reduced bacterial load in the
kidneys. Together, our data suggest that neutrophils are an
important pathogenic factor in this model, and forskolin-
mediated inhibitory effects on leukocytes chemotaxis and
production of proinﬂammatory mediators will have favor-
able effects in tissue damage and bacteria access to the
underlying tissue during acute pyelonephritis.
In addition to inﬂammatory cells, we generated a series of
data which strongly support the RTEC-dependent mecha-
nism by which forskolin confers the protection of kidneyajp.amjpathol.org - The American Journal of Pathology
Cyclic AMP and Acute Pyelonephritisinfection. First, our in vitro cell culture data clearly indicate
that RTECs produce a wide range and signiﬁcant amounts of
proinﬂammatory mediators in response to E. coli stimulation;
forskolin treatment had inhibitory effects on the production
of most key proinﬂammatory mediators by RTECs, sug-
gesting that inhibition of renal cell production of proin-
ﬂammatory mediators represents an important mechanism of
forskolin effect. Second, our data from the in vitro model of
internalization indicate a critical role for forskolin in limiting
E. coli invasion of RTECs. Although previous studies have
found that forskolin-induced cAMP can down-regulate inter-
nalization of UPEC into bladder epithelial cells, thus limiting
bacteria entering the bladder; such a role was not previously
described in renal epithelial cells. Our results show that for-
skolin treatment clearly reduced viable intracellular bacteria
in RTECs and increased viable bacteria that had exited the
cells, suggesting that forskolin has inhibitory effect on E. coli
invasion of RTECs, which may offer an explanation of
forskolin-mediated reduction of bacterial load in the kidney.
Previous studies have suggested that elevated cAMP can
reduce bacterial uptake by epithelial cells through inhibiting
activation of Rho GTPase Rac-1 in a PKA-dependent
manner.35 The Rho GTPase Rac-1 is an important mediator
of bacterial invasion, whose activation leads to actin ﬁlament
accumulation and cytoskeleton rearrangement at sites of bac-
terial entry and, consequently, bacterial internalization. In
addition, the cAMPsignaling system iswell known to regulate
and modulate exocytosis in a variety of secretory cells,18
and the elevated cAMP can trigger bacterial exocytosis
through regulating vesicular trafﬁcking in a PKA-Slac2c-
GTPase Rab27-dependent manner.19,36 Therefore, forskolin-
mediated inhibition of invasion of RTECs could be regarded
as resulting from cAMP negatively regulated bacterial uptake
and positively regulated exocytosis. Third, the data from the
neutrophil depletion experiment indicate that administration
of forskolin in neutrophil-depleted mice still reduced bacterial
load in kidneys and attenuated tissue destruction, suggesting
that forskolin can mediate its protective effect on kidney
infection through acting on renal parenchymal cells.
In general, forskolin-inducible cAMP signaling in leuko-
cytes is thought to be associated with inhibition of cellular
responses; therefore, we explored the possibility that forskolin
could affect antibacterial functions (eg, phagocytosis and ROS
activity) of inﬂammatory cells, which may have unfavorable
effects in acute pyelonephritis. Previous studies have found
that elevation of intracellular cAMP is able to mediate the
inhibition of receptor (FcR, complement receptor)-mediated
phagocytosis and ROS activity in human neutrophils.17,37
However, our data in the phagocytosis experiments (in the
absence of FcR and complement receptor ligands) indicate that
forskolin treatment had no effect on dextran-bead uptake rates
of neutrophils and macrophages (data not shown), which do
not support the inhibitory role of forskolin in phagocytosis,
although we cannot exclude the possibility that in vivo, in the
presence of FcR or complement receptor ligands, forskolin
may have an inhibitory effect on phagocytosis. Our data in theThe American Journal of Pathology - ajp.amjpathol.orgROS experiments indicate that forskolin treatment resulted
in a small reduction in ROS activity of neutrophils, which is
consistent with the previous observation, but forskolin
treatment had no apparent effect on ROS activity of mac-
rophages. Although ROS activity of neutrophils is essential
to host defense, their improper activation often causes
unwanted tissue damage. Therefore, forskolin-mediated
mild inhibition of superoxide generation may have a favor-
able effect in acute pyelonephritis. Nevertheless, on the basis
of our current data in vitro and in vivo, it is tempting to
speculate that forskolin may not mediate signiﬁcantly un-
favorable effects through acting on inﬂammatory cells in
acute pyelonephritis.
On the basis of our present ﬁndings together with the
literature on the properties of cAMP/forskolin,15e17,19,38 we
propose a mechanism by which forskolin confers the pro-
tection against murine acute pyelonephritis. During UTI,
elevation of intracellular cAMP by forskolin has a direct
inﬂuence on the cellular migratory apparatus of inﬂamma-
tory cells (eg, neutrophils, monocytes/macrophages) and
results in the inhibition of their migration (Figure 8).
Elevation of intracellular cAMP also has inhibitory effects
on the production of most proinﬂammatory cytokines (eg,
KC, IL-1b, TNF-a, and MCP-1) in both RTECs and
inﬂammatory cells. Furthermore, elevation of intracellular
cAMP has a suppressive effect on E. coli invasion of
RTECs. Consequently, the lowered migratory capacity of
inﬂammatory cells and reduced local production of proin-
ﬂammatory mediators lead to the attenuation of cellular
inﬁltration and tissue damage; the attenuated tissue damage
and bacteria invasion of RTECs contribute to the reduced
bacteria load in the kidneys.
Conclusion
This study ﬁnds that activation of the endogenous anti-
inﬂammatory mediator cAMP by forskolin confers protec-
tion in murine acute pyelonephritis and highlights the
importance of excessive innate immune responses and in-
vasion of renal epithelial cells in the pathogenesis of acute
pyelonephritis. Our ﬁndings together with previous obser-
vations in bladder infection strongly suggest that pharma-
cotherapies that increase intracellular cAMP could be
alternative or additional therapies for improving current
treatment of acute pyelonephritis.
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